MIRA INFORM REPORT

 

 

Report No. :

316754

Report Date :

11.04.2015

 

IDENTIFICATION DETAILS

 

Name :

MISSIONPNARMA AS

 

 

Registered Office :

Vassingeradvej 9, Lynge,

 

 

Country :

Denmark

 

 

Financials (as on) :

2013

 

 

Date of Incorporation :

06.12.2002

 

 

Com. Reg. No.:

26902398

 

 

Legal Form :

Limited company

 

 

Line of Business :

Wholesale of Pharmaceutical and Nursing Goods.

 

 

No. of Employees :

45 [2013]

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Denmark

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

DENMARK - ECONOMIC OVERVIEW

 

This thoroughly modern market economy features a high-tech agricultural sector, state-of-the-art industry with world-leading firms in pharmaceuticals, maritime shipping and renewable energy, and a high dependence on foreign trade. Denmark is a member of the European Union (EU); Danish legislation and regulations conform to EU standards on almost all issues. Danes enjoy a high standard of living and the Danish economy is characterized by extensive government welfare measures and an equitable distribution of income. Denmark is a net exporter of food and energy and enjoys a comfortable balance of payments surplus, but depends on imports of raw materials for the manufacturing sector. Within the EU, Denmark is among the strongest supporters of trade liberalization. After a long consumption-driven upswing, Denmark's economy began slowing in 2007 with the end of a housing boom. Housing prices dropped markedly in 2008-09 and, following a short respite in 2010, have since continued to decline. Household indebtedness is still relatively high at more than 275% of gross disposable income in the first half of 2013. The global financial crisis has exacerbated this cyclical slowdown through increased borrowing costs and lower export demand, consumer confidence, and investment. Denmark made a modest recovery in 2010, in part because of increased government spending; however, the country experienced a technical recession in late 2010-early 2011. Historically low levels of unemployment rose sharply with the recession and have remained at about 6% in 2010-13, based on the national measure, about two-thirds average EU unemployment. An impending decline in the ratio of workers to retirees will be a major long-term issue. Denmark maintained a healthy budget surplus for many years up to 2008, but the budget balance swung into deficit in 2009, where it remains. In spite of the deficits, the new coalition government delivered a modest stimulus to the economy in 2012. Nonetheless, Denmark's fiscal position remains among the strongest in the EU with public debt at about 46% of GDP in 2013. Despite previously meeting the criteria to join the European Economic and Monetary Union (EMU), so far Denmark has decided not to join, although the Danish krone remains pegged to the euro.

 

Source : CIA


Company summary

 

business Name                

Missionpnarma A/S

Country

DENMARK

Company Registration Number

26902398

Activity Code

464610

Activity Description

Wholesale of pharmaceutical and nursing goods

Company Status

Active (Active)

Latest Turnover Figure

537.927.000 DKK

Latest Shareholder Equity Figure

124.385.000 DKK

Local Description

Businesses at this level are regarded as having excellent creditworthiness. Small businesses only have a limited possibility of achieving this level. Businesses at this level are in a class by themselves and will have results or financial foundations which are among the best in the country. The credit risk is regarded as minimal.

 

 

Basic Information

 

business Name

Missionpharma A/S

Registered Company Name

Missionpharma A/S

Company Registration Number

26902398

Country

DENMARK

Date of Company Registration

06/12/2002

Legal Form

Limited company

Company Status

Active (Active)

Currency of this Report

DKK

Principal Activity Code

464610

Principal Activity Description

Wholesale of pharmaceutical and nursing goods

Contact Address

Vassingeradvej 9, Lynge 3540

Contact Telephone Number

48163200

 

 

Main Address

 

Address

Country

Telephone

Vassingeradvej 9, Lynge 3540

DENMARK

48163200

 

 

Activities

 

Activity Code

Activity Description

464610

Wholesale of pharmaceutical and nursing goods

464620

Wholesale of medical and hospital goods

 

 

Email Addresses

 

info@missionpharma.com

 

 

Web Pages

 

www.missionpharma.com

 

 

Employee Information

 

Year

Number of Employees

2013

45

2012

51

2012

50

 

 

Real estate

 

Real Estate

No

 

 

Other Trading Information

 

Type

Name

Business name

International Project Services A/S

Business name

Missionpharma International A/S

Business name

Missionpharma International Project Services A/S

Business name

Missionpharma International Relief Services A/S

 

 

Global Trading Information

Export              -                       Europe

Import               -                       -

 

 

Other Information

 

Type

Text

No. of employees

According to information from the business the number of employees is 50.

Historical data

In 2003 the company took over the activities previously carried on by Missionpharma Interna. Proj. Services A/S (16929484.)

Capital conditions

fully paid up

 

 

Additional Accounts Information

 

Date Format                             MM-DD

Accounts Start Date                  01-01

Accounts End Date                   12-31

 

 

Profit and Loss

 

 

 

Financial Year

2013

2012

2012

Number of Weeks

52

35

52

Currency

DKK

DKK

DKK

Revenue

537.927.000

387.645.000

619.055.000

Operating Profit

69.046.000

48.453.000

36.595.000

Retained Profit

44.083.000

35.246.000

26.429.000

 

 

Balance Sheet

 

 

 

Financial Year

2013

2012

2012

Number of Weeks

52

35

52

Currency

DKK

DKK

DKK

TOTAL ASSETS

214.241.000

230.154.000

246.801.000

Other Reserves

124.385.000

106.596.000

85.828.000

 

 

Share capital Structure

 

Nominal Share Capital

1.000.000  DKK

 

 

Shareholders

 

Shareholder

Address

% Shares Held

P. Ginnerup ApS

Vassingerødvej 9 Lynge 3540 DNK

60

 

 

Current Directors

 

Name

 

Appointment Date

Position

Kim Erik Ginnerup

03/04/2013

Managing director

Poul Lindof

05/01/2010

General manager

Jean-Marc Pierre René Leccia

20/07/2012

Chairman

Denis Georges Fernand Maurice

20/07/2012

Deputy Chairman

Eric Pierre Jean Muris

20/07/2012

Member of the board

 

Name

Appointment Date

Position

Kim Erik Ginnerup

03/01/2011

Member of the board

Poul Lindof

29/01/2015

Finance

 

 

Ultimate Holding Parent

 

Ultimate Holding Company Name

P. Ginnerup ApS

Ultimate Holding Company Country

 

 

 

Subsidiary Companies

 

Subsidiary Name

Country

PharmaDanica A/S

DENMARK

Missionpharma Logistics Pvt Ltd

INDIA

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.37

UK Pound

1

Rs.91.60

Euro

1

Rs.66.49

 

INFORMATION DETAILS

 

Analysis Done by :

SUB

 

 

Report Prepared by :

NIT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.